{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:37:02Z","timestamp":1792597022901,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtha.2025.12.033","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:34:17Z","timestamp":1770078857000},"page":"1230-1241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic therapy in patients with atrial fibrillation: unresolved issues and future directions"],"prefix":"10.1016","volume":"24","author":[{"given":"Alexander P.","family":"Benz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.12.033_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.12.033_bib3","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2025.12.033_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtha.2025.12.033_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib13","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.12.033_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.12.033_bib21","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.12.033_bib22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.12.033_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib24","article-title":"Comparing CHA(2)DS(2)-VA and CHA(2)DS(2)-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort","volume":"43","author":"Teppo","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2025.12.033_bib25","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation","volume":"134","author":"Oldgren","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib27","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1161\/CIRCULATIONAHA.120.053100","article-title":"Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation","volume":"143","author":"Benz","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/CIRCULATIONAHA.125.076725","article-title":"Biomarker-based ABC-AF risk scores for personalized treatment to reduce stroke or death in atrial fibrillation\u2014a registry-based multicenter randomized controlled study","volume":"152","author":"Oldgren","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.033_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.12.033_bib33","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib35","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib37","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.123.066279","article-title":"Efficacy and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: an individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib38","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacc.2025.05.060","article-title":"Outcomes in older patients after switching to a newer anticoagulant or remaining on warfarin: the COMBINE-AF substudy","volume":"86","author":"Nicolau","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.12.033_bib40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2025.12.033_bib42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.12.033_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib44","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIRCULATIONAHA.124.070172","volume":"150","author":"van Doorn","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.12.033_bib46","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jtha.2025.12.033_bib47","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.0000000000000495","article-title":"Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial","volume":"36","author":"Harel","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jtha.2025.12.033_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081961","article-title":"Protocol for a randomised controlled trial comparing warfarin with no oral anticoagulation in patients with atrial fibrillation on chronic dialysis: the Danish Warfarin-Dialysis (DANWARD) trial","volume":"14","author":"Ballegaard","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.12.033_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib52","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical atrial fibrillation in older patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib53","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib55","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA(2)DS(2)-VASc score in subclinical atrial fibrillation: insights from ARTESiA","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.12.033_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(24)00475-7","article-title":"Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial","volume":"24","author":"Shoamanesh","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib58","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1093\/eurheartj\/ehae596","article-title":"Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"45","author":"Schnabel","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.12.033_bib59","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.124.069903","article-title":"Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: insights from the ARTESiA trial","volume":"150","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.12.033_bib60","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib61","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.12.033_bib62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.hrthm.2025.05.021","article-title":"Ablation of atrial fibrillation and risk of stroke: a meta-analysis","volume":"23","author":"Providencia","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jtha.2025.12.033_bib63","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.7326\/ANNALS-25-00253","article-title":"Catheter and surgical ablation for atrial fibrillation : a systematic review and meta-analysis","volume":"178","author":"Montan\u00e9","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib64","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jama.2025.14679","article-title":"Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation: the ALONE-AF randomized clinical trial","volume":"334","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.12.033_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib66","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaneurol.2025.1337","article-title":"Residual risk of recurrent stroke despite anticoagulation in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"82","author":"McCabe","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib67","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib70","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.12.033_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034758","article-title":"Residual stroke risk among patients with atrial fibrillation prescribed oral anticoagulants: a patient-level meta-analysis from COMBINE AF","volume":"13","author":"Johnson","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.12.033_bib72","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib73","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacep.2025.02.047","article-title":"Introducing the Fourth Left Atrial Appendage Occlusion Study","volume":"11","author":"McIntyre","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jtha.2025.12.033_bib74","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib75","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.12.033_bib76","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1474-4422(21)00298-2","article-title":"Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial","volume":"20","author":"Schreuder","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib77","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0140-6736(25)00333-2","article-title":"Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial","volume":"405","author":"Veltkamp","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S1474-4422(21)00264-7","article-title":"Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib79","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(23)02025-1","article-title":"Anticoagulation in patients with cerebral amyloid angiopathy","volume":"402","author":"Shoamanesh","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib80","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(23)00315-0","article-title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials","volume":"22","author":"Al-Shahi Salman","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.12.033_bib81","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ehjcvp\/pvab044","article-title":"Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials","volume":"8","author":"Benz","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2025.12.033_bib82","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.033_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.606","article-title":"Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF","volume":"45","author":"Tannu","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.12.033_bib84","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.12.033_bib85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.033_bib86","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib87","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.12.033_bib88","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.12.033_bib90","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:17:18Z","timestamp":1781939838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1538783626000577"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.033","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic therapy in patients with atrial fibrillation: unresolved issues and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}